

SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 01/23/18

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Reduce the risk of major adverse cardiac events (MACE) in patients with Chronic Heart Failure and significant Coronary Artery Disease (2) Prevention of Symptomatic VTE and VTE-related death in high-risk, medically ill pts (2) Reduce the risk of MACE in patients with coronary or Peripheral Artery Disease (2) VTE prophylaxis in ambulatory cancer patients receiving chemo at high-risk for VTE (2) Long-term Prevention of Recurrent Symptomatic VTE (2) Infrainguinal revascular (2)	Phase III Phase III Filed 12/17 Phase III Approved 10/17 Phase III	
	INVOKANA® (canagliflozin)	Pediatric VTE (2) Diabetic Nephropathy (2) Reduce the risk of death in type 2 diabetes with established, or risk for, cardiovascular disease. (CANVAS /CANVAS-R) (2)	Phase III Phase III Filed 9/17	Phase III Filed 10/17
Immunology	TREMFYA® (guselkumab)	Moderate to Severe Plaque Psoriasis Psoriatic arthritis	Approved 7/17 Phase III	Approved 11/17 Phase III
	SIMPONI ARIA® (golimumab)	Ankylosing spondylitis Psoriatic arthritis Juvenile Idiopathic Arthritis (JIA)	Approved 10/17 Approved 10/17 Phase III	
	STELARA® (ustekinumab)	Adolescents Psoriasis Pediatric Psoriasis Ulcerative Colitis	Approved 10/17 Phase III Phase III	Approved 6/15 Phase III Phase III
Infectious Diseases and Vaccines	SYMTUZA™ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)	Single tablet regimen for HIV in treatment naïve patients and treatment experienced patients (2)	Filed 9/17	Approved 9/17
	JULUCA® (rilpivirine and dolutegravir)	Single tablet regimen for HIV in treatment experienced patients (2)	Approved 11/17	Filed 5/17
	Rilpivirine Long Acting nanosuspension for injection cadazolid	HIV Infection Clostridium difficile-associated diarrhea (2)	Phase III Phase III	Phase III Phase III
Neuroscience	esketamine	Treatment-resistant depression Major depressive disorder with imminent risk for suicide	Phase III Phase III	Phase III Phase III
	ponesimod	Relapsing multiple sclerosis (2)	Phase III	Phase III
	paliperidone palmitate 6 month long-acting injectable	Maintenance treatment of schizophrenia	Phase III	Phase III
Oncology	DARZALEX®	Frontline multiple myeloma transplant eligible in combination with bortezomib, thalidomide and dexamethasone (MMY 3006) (2)	Phase III	Phase III
		Frontline multiple myeloma transplant ineligible patients in combination with bortezomib, melphalan, and prednisone (MMY 3007) (2)	Filed 11/17	Filed 11/17
		Frontline multiple myeloma transplant ineligible patients in combination with lenalidomide and low dose dexamethasone (MMY 3008) (2)	Phase III	Phase III
		Relapsed Refractory MM 1+ prior lines w/PomDex (2)	Phase III	Phase III
		Amyloidosis (AMY 3001) (2)	Phase III	Phase III
		Subcutaneous (SC) formulation (MMY3012) (2)	Phase III	Phase III
		Smoldering multiple myeloma (SMM3001) (2)	Phase III	Phase III
	IMBRUVICA® (ibrutinib)	Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2)	Phase III	Phase III
		Relapsed/refractory patients with Indolent Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2)	Phase III	Phase III
		Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma in combination with R-CHOP (randomized study DBL3001) (2)	Phase III	Phase III
		Previously Treated Adults with Waldenstrom's Macroglobulinemia with Rituximab (PCYC-1127) (2)	Phase III	Phase III
		Frontline Chronic Lymphocytic Leukemia (Young and Fit) (in combination with Rituximab) (ECOG 1912) (2)	Phase III	Phase III
	apalutamide (ARN-509)	Frontline Chronic Lymphocytic Leukemia in combination with obinutuzumab (PCYC-1130) (2)	Phase III	Phase III
Frontline Chronic graft-versus-host-disease (cGVHD) (2)		Phase III	Phase III	
Prostate cancer pre-metastatic castration-resistant Metastatic hormone sensitive prostate cancer Localized prostate cancer		Filed 10/17 Phase III Phase III	Phase III Phase III Phase III	
Prostate Cancer metastatic castration resistant chemotherapy naïve		Phase III	Phase III	
Relapsed Ovarian Cancer (2)		Phase III		
ZYTIGA® (abiraterone acetate)	Prostate Cancer Newly Diagnosed Hormone Naïve Metastatic	Filed 9/17	Approved 11/17	
Pulmonary Hypertension	OPSUMIT®	Fontan-palliated in adolescent (>12 years old) and Pediatric pulmonary arterial hypertension	Phase III Phase III	Phase III Phase III
	UPTRAVI® IV	Pulmonary arterial hypertension	Phase III	Phase III

* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; SYMTUZA developed in collaboration with Gilead Sciences; EDURANT STR developed in collaboration with Viiv Healthcare; YONDELIS developed in collaboration with PharmaMar S.A.; XARELTO co-developed with Bayer HealthCare; paliperidone palmitate includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company Ponesimod and Cadazolid developed by Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson

Janssen Pharmaceutical Companies of Johnson & Johnson
Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
 Selective Highlights as of January 23, 2018

NMEs APPROVED 2017/2018	NMEs IN REGISTRATION	NME PLANNED FILINGS 2018-2021*	
Immunology	Oncology	Oncology	Neuroscience
TREMFYA® (guselkumab) Psoriasis	Apalutamide (ARN-509) (US) Pre-metastatic prostate cancer	Imetelstat Myelofibrosis	Esketamine Treatment resistant depression
		Erdafitinib (FGFRI kinase inhibitor) Urothelial cancer	Seltorexant (JNJ-7922) Adjunctive treatment for major depressive disorder
		Niraparib Metastatic castration-resistant prostate cancer (mCRPC)	Ponesimod Relapsing multiple sclerosis
		Apalutamide (ARN-509) (EU) Pre-metastatic prostate cancer	Infectious Diseases & Vaccines
			Lumicitabine (JNJ-1575) RSV infection
			Pimodivir (JNJ-3872) Influenza A
			JNJ-1860 (ExPEC vaccine) Bacterial infection

*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Seltorexant (Orexin - 2) antagonist codeveloped with Minerva Neurosciences; Imetelstat licensed from Geron; Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; Erdafitinib discovered in collaboration with Astex Pharmaceuticals, Inc.; Ponesimod developed by Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson

